The Anti-fibrotic Actions of Relaxin Are Mediated Through a NO-sGC-cGMP-Dependent Pathway in Renal Myofibroblasts In Vitro and Enhanced by the NO Donor, Diethylamine NONOate
Chao Wang, Barbara K Kemp-Harper, Martina Kocan, Sheng Yu Ang, Tim D Hewitson, Chrishan S Samuel
Frontiers in Pharmacology | FRONTIERS MEDIA SA | Published : 2016
Awarded by National Health and Medical Research Council (NHMRC) of Australia
Awarded by NHMRC Senior Research Fellowship
We sincerely thank Corthera Inc (San Carlos, CA, USA; a subsidiary of Novartis AG, Basel, Switzerland) for providing the human recombinant relaxin used in this study. This study was supported by a National Health and Medical Research Council (NHMRC) of Australia Project Grant (GNT628634) to CS and TH, and by a NHMRC Senior Research Fellowship (GNT1041766) to CS.